EZH2 Inhibition in Advanced Epithelioid Sarcoma: Real-World Evidence of Target Validation and Implications for Next-Generation Inhibitor Development
This real-world study of 17 advanced epithelioid sarcoma patients treated with tazemetostat prior to its 2026 global withdrawal demonstrates that EZH2 inhibition retains significant antitumor activity and a favorable safety profile, thereby validating the target for next-generation inhibitor development despite the first-generation agent's safety limitations.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Some cancers are driven by a broken switch inside the cell's control room. In a rare and aggressive type of soft tissue cancer called epithelioid sarcoma, a specific protein called INI1 is missing. Without this protein, the cell loses its ability to regulate its own growth. Scientists discovered that another protein, known as EZH2, acts like a heavy hand, pressing down on the genes that should keep the cancer in check. In theory, if you could block EZH2, you might release those brakes and allow the cancer to stop growing. This idea led to the development of a drug called tazemetostat, which was designed to turn off EZH2. However, the path to using this drug has been rocky. While it showed promise for this specific cancer, the drug was later pulled from the global market because it caused dangerous blood cancers in patients with a different type of lymphoma. This created a difficult question for doctors and researchers: was the danger caused by the drug itself, or was it a flaw in the specific molecule used? More importantly, does the strategy of blocking EZH2 actually work for epithelioid sarcoma, or was the hope misplaced?
To answer this, a team of researchers in China looked back at a group of patients who had received the drug before it was withdrawn. They focused on seventeen people with advanced epithelioid sarcoma who were treated at a hospital in Hainan. This location was key because a special policy allowed these patients to access the medication early, before it was officially approved in China. The researchers gathered data on how these patients responded to the treatment, tracking whether their tumors shrank, stayed the same, or grew larger. They also watched closely for any side effects, paying particular attention to whether the drug caused the blood cancers that had led to its global withdrawal. The group included patients who took the drug alone and others who took it alongside other treatments, giving the scientists a clear view of how the drug performed on its own.
The results offered a glimmer of hope for the future of this treatment strategy. Among the patients who could be fully evaluated, the drug worked well for a significant portion of them. More than one-third of the patients saw their tumors shrink, and nearly all of them saw their disease stop growing for a time. When the researchers looked specifically at the patients who took the drug alone, without any other medicines mixed in, the results were even stronger. In this group, every single patient either saw their tumor shrink or their disease stabilize. This suggests that the drug itself has the power to fight the cancer, independent of other treatments. The benefits lasted for a long time, with many patients seeing their tumors controlled for over a year, and some for much longer. One patient achieved a complete disappearance of their cancer, which lasted for more than two years.
Safety was another major concern, given the history of the drug. In this group of seventeen patients, the treatment was well tolerated. The side effects were mild, mostly consisting of tiredness, nausea, or a slight drop in appetite. Crucially, none of the patients developed the secondary blood cancers that had caused the drug to be pulled from the market elsewhere. While the number of patients was too small to say with absolute certainty that the risk is zero, the fact that no such cases appeared in this group is a significant observation. It suggests that the danger of blood cancer might be specific to how the drug interacts with blood cells, rather than a universal problem with the idea of blocking EZH2.
The study does not claim that the problem is solved. The researchers are careful to note that their group was small, and the results, while encouraging, need to be confirmed in larger groups of people. The confidence in the exact success rate is limited by the small number of patients, meaning the true effectiveness could be higher or lower than what was observed. However, the data provides a strong reason to keep looking for better versions of this drug. The findings suggest that the biological target is real and that blocking it can control this difficult cancer. The challenge now is to design the next generation of drugs that can keep the cancer under control without causing harm to the blood system. For patients with epithelioid sarcoma, who have very few options, this research keeps the door open for a future where the treatment is both effective and safe.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.